House appropriators are demanding that FDA dramatically revise its compounding policies, suggesting in report language that the agency overreached its statutory authority by penning a memorandum of understanding that covers dispensing, and that the agency went against Congressional intent by prohibiting office-use compounding. The lawmakers ask FDA to revamp the MOU to remove dispensing and to scrap its ban on office-use compounding. The lawmakers tell FDA that office-use compounding, which FDA has deemed not permissible for traditional compounders, was intended...